Pulsenmore has signed a commercial agreement with Clalit Health Services, Israel’s largest health maintenance organization, to provide at-home ultrasound monitoring for women undergoing IVF and fertility preservation treatment. The agreement is potentially valued at approximately $4.5 million over five years following an 18-month pilot.
The service will be operated through Beilinson NEXT, Beilinson Medical Center’s virtual hospital. Patients will perform follicular monitoring scans from home using Pulsenmore FC, a patient-operated ultrasound device, with step-by-step guidance in a mobile app. Scan data are transmitted to the care team for remote interpretation and clinical oversight.
Fertility treatment often requires frequent in-clinic transvaginal ultrasound scans. Pulsenmore FC is designed to monitor follicle development and endometrial thickness for timing of trigger injections and egg retrieval while reducing the need for repeated clinic visits.
Pulsenmore reported results in June 2025 from a controlled clinical study at Beilinson Medical Center that demonstrated a strong safety profile, with high concordance between at-home measurements and in-clinic assessments.
“We believe this agreement represents a global breakthrough in how fertility care can be delivered,” said Dr. Elazar Sonnenschein, CEO and founder of Pulsenmore. “We are enabling a new model of care that respects patients’ time, privacy, and daily lives, while maintaining clinical oversight.”
Dr. Eytan Wirtheim, CEO of Clalit, said: “This service fits seamlessly into Clalit’s new strategic vision, under which ‘Medicine has left the building’: any medical service that can be provided to patients from the comfort and calm of their homes, instead of requiring visits to hospital clinics, will be offered in this way as well – provided it can be delivered at the same level of quality as in the hospital setting.”
Pulsenmore also supplies Clalit with Pulsenmore ES, its home prenatal ultrasound solution, which received FDA De Novo authorization. In October 2024, Pulsenmore signed a binding agreement with Clalit for an additional 25,000 Pulsenmore ES units over five years.
